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Abstratct 20 
The resistance of six casein-derived peptides, including antihypertensive peptides RYLGY, 21 
AYFYPEL and YQKFPQY, to simulated gastrointestinal digestion and the effect on activity 22 
were evaluated. After digestion, peptides RYLGY, AYFYPEL, and YQKFPQY were partly 23 
hydrolyzed by digestive enzymes. From these, RYLGY and AYFYPEL maintained a potent 24 
ACE-inhibitory activity, with IC50 values as low as 9.3 and 4.7 μg mL-1, respectively. Several 25 
of the digestion fragments, previously identified by HPLC-MS and synthetized, showed 26 
potent ACE-inhibitory, which could explain the in vitro activity of the digests. A notable 27 
antioxidant activity was also observed. Furthermore, since AYFYPEL was less susceptible to 28 
digestion, we focused on the antihypertensive activity in SHR of the main digestion fragments 29 
of RYLGY. Interestingly, these peptides showed moderate effects in vivo. This finding 30 
suggests that, besides undigested fraction that could also contribute in the in vivo effects of 31 
RYLGY and AYFYPEL, other minor fragments may participate. 32 
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1. Introduction 37 
It is known that bioactive peptides may undergo physiological transformations that 38 
determine their bioavailability and activity in the organism. In fact, gastrointestinal digestion 39 
play an important role in the formation and degradation of bioactive peptides. Although in 40 
vivo methods, using animals or humans, usually provide the most accurate results, they are 41 
costly and time consuming. Therefore, a great interest has been dedicated on the development 42 
and application of in vitro approaches (Hur, Lim, Decker, & McClements, 2011). Sequential 43 
hydrolysis with pepsin and pancreatic extracts have been applied to mimic the gastrointestinal 44 
conditions and to evaluate the stability of angiotensin-converting enzyme (ACE) inhibitory 45 
peptides. This hydrolysis process together with in vitro studies with epithelial intestinal Caco-46 
2 cells have allowed elucidating whether the released sequences have physiological relevance 47 
in blood pressure regulation. For instance, casein-derived peptides IPP and VPP, have been 48 
demonstrated to be highly resistant to digestive peptidases (Ohsawa et al., 2008), to be 49 
absorbed through intestinal epithelium (Foltz et al., 2008), reaching blood circulation in an 50 
intact and active form (Van Platerink, Janssen, Horsten, & Haverkamp, 2006; Foltz et al., 51 
2007). Following a similar procedure, it was found that peptide LHLPLP resisted simulated 52 
gastrointestinal digestion, but it was hydrolysed by intestinal peptidases to the active form, 53 
HLPLP, prior to its absorption (Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008; Quirós, 54 
Contreras, Ramos, Amigo, & Recio 2009). Interestingly, this pentapeptide was detected in 55 
human plasma samples after the consumption of a peptide-enriched drink (Van Platerink et 56 
al., 2006).  57 
Gastrointestinal digestion may also lead the formation of active fragments from 58 
inactive or less active precursors. For example, the antihypertensive β-CN fragment, 59 
KVLPVP, was released from the inactive precursor KVLPVPQ after pancreatic digestion 60 
(Maeno, Yamamoto, & Takano, 1996). Miguel, Aleixandre, Ramos, & López-Fandiño (2006) 61 
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found, after simulated gastrointestinal digestion of egg white-derived peptides YAEERYPIL 62 
and RADHPFL, that released fragments YPI and RADHP might contribute on the in vivo 63 
effects of precursor peptides.  64 
Two potent ACE-inhibitory peptides were identified in a peptic casein hydrolysate 65 
which corresponded to RYLGY [αS1-CN f(90–94)], and AYFYPEL [αS1-CN f(143–149)] 66 
(Contreras, Carrón, Montero, Ramos, & Recio, 2009). These peptides also exerted significant 67 
antihypertensive activity in spontaneously hypertensive rats (SHR) after both oral acute and 68 
long-term administration (Contreras et al., 2009; Sánchez et al., 2011). Additional 69 
cardiovascular benefits, such as significant improvement of the aorta and mesenteric 70 
acetylcholine relaxations, increase of the aortic endothelial nitric-oxide synthase (eNOS) 71 
expression and decrease of the left ventricular hypertrophy and intersticial fibrosis were also 72 
observed in SHR after administration of this casein hydrolysate (Sánchez et al., 2011). The 73 
hydrolysis process was scaled up to produce, under food grade conditions, an antihypertensive 74 
ingredient containing the most active peptides RYLGY and AYFYPEL (Contreras et al., 75 
2011). Furthermore, no treatment-related toxicity was detected when casein hydrolysate was 76 
orally administered to Wistar rats at doses of 1000 mg kg-1 for 4 weeks or 2000 mg kg-1 in a 77 
single oral dose, which supports its safe use as functional ingredient (Anadón et al., 2010).  78 
The main objective of the present study was to evaluate the stability of peptides 79 
previously identified in a casein hydrolysate against a process simulating physiological 80 
gastrointestinal digestion. Moreover, ACE-inhibitory, antihypertensive, and antioxidant 81 
activities of peptide fragments released during digestive process were also investigated in 82 
order to identify the in vivo active sequences. 83 
 84 
2. Material and methods 85 
 86 
2.1. Peptide synthesis  87 
 5
All peptides were prepared by conventional Fmoc solid-phase synthesis, using a 431A 88 
peptide synthesizer (Applied Biosystems, Uberlingen, Germany). The purity of these 16 89 
peptides was verified by analytical RP-HPLC-MS (Quirós et al., 2008). Peptides 90 
corresponded to six casein-derived sequences found in a peptic hydrolysate: RYLGY, 91 
AYFYPEL, FVAPFPEV, VAPFPEVF, YQKFPQY, and HLPLPLL; and peptide fragments 92 
there of generated during simulated gastrointestinal digestion: RY, YLG, RYLG, LGY, RYL, 93 
YLGY, AYFYPE, FYPEL, YQK, and FPQY were studied. 94 
 95 
2.2. Simulated gastrointestinal digestion 96 
 97 
The two stage-hydrolysis process simulating gastrointestinal digestion was carried out 98 
according to Gómez-Ruiz, Ramos, & Recio (2004) with the exception that the enzyme 99 
employed was pepsin (E.C. 3.4.23.1; 1:10,000; 570 U mg-1) (Sigma, St. Louis, MO, USA). 100 
The simulated gastrointestinal digestion was carried independently and in duplicate  101 
 102 
2.3. Peptide sequencing by RP-HPLC-MS/MS 103 
 104 
Digests were analysed by RP-HPLC-MS/MS using an Agilent 1100 HPLC System 105 
(Agilent Technologies, Waldbron, Germany) connected on-line to an Esquire 3000 106 
quadrupole ion trap (Bruker Daltonik GmbH, Bremen, Germany) equipped with an 107 
electrospray ionisation source, as previously described (Contreras et al., 2010). 108 
 109 
2.4. Measurement of ACE-inhibitory activity 110 
 111 
 6
ACE-inhibitory activity was measured by spectrophotometric assay of Cushman & 112 
Cheung (1971) with some modifications, as reported by Quirós et al. (2007). The ACE-113 
inhibitory activity of the samples was expressed as IC50 (peptide concentration required to 114 
inhibit the original ACE activity by 50%) and was determined in triplicate.  115 
 116 
2.5. Measurement of antioxidant activity 117 
 118 
Oxygen radical absorbance capacity-fluorescein (ORAC-FL) assay was based on the 119 
method applied by Dávalos, Gómez-Cordovés, & Bartolomé (2004) and reported by 120 
Contreras, Hernández-Ledesma, Amigo, Martín-Álvarez, Recio (2011). This assay was also 121 
performed in triplicate for each sample. 122 
 123 
2.6. Measurement of antihypertensive activity 124 
 125 
All the experiments were performed according to the European Union guidelines for 126 
the ethical care and use of laboratory animals (European Directive 86/609/CEE). Male SHR 127 
12 week old (Elevage Janvier, Le Genest Saint Isle, France) were housed in groups of four 128 
rats and maintained at 23ºC with 12 h light/dark cycles. The rats received, by oral 129 
administration using a canula, a single dose of the synthesized peptides (5 mg kg-1 of body 130 
weight) dissolved in ultrapure water. Systolic blood pressure (SBP) was measured in awake 131 
rats using the CODA tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) 132 
as was described previously (Sánchez et al., 2011). Blood pressure measurement was carried 133 
out before peptides administration, and at different times post-administration.  134 
 135 
 136 
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2.7. Statistical analysis 137 
 138 
Data were expressed as mean ± standard error of the mean (SEM). Statistical 139 
calculations for significant differences between SBP before administration and the different 140 
times postadministration were performed by Student's t test for paired data and P values of 141 
less than 0.05 was considered significant. The GraphPad Prism 5 software program 142 
(GraphPad Software Inc., San Diego, California, USA) was used. 143 
 144 
 145 
3. Results and discussion 146 
 147 
3.1. Effect of simulated gastrointestinal digestion on ACE-inhibitory activity of casein 148 
peptides 149 
 150 
The hydrolysis pattern of synthetic casein peptides subjected to simulated 151 
gastrointestinal digestion was evaluated by HPLC-MS/MS. This technique also allowed the 152 
identification of peptide sequences released during the digestive process. As shown in Fig. 1, 153 
six peptides were hydrolysed by digestive enzymes, but the degree of hydrolysis was 154 
different. Peptides RYLGY, YQKFPQY, AYFYPEL, and FVAPFPEV were partially 155 
resistant to gastrointestinal digestion, whereas peptides VAPFPEVF and HLPLPLL were 156 
totally hydrolysed. After the action of digestive enzymes, 93% of peptide RYLGY was 157 
hydrolysed, and RY, YLG, RYLG, YLGY, and RYL (Fig. 1A) appeared as major peptide 158 
fragments in the final digest. In the case of peptide AYFYPEL, 47% of undigested peptide 159 
remained intact at the end of the digestive process (Fig. 1B). This peptide and a shorter 160 
peptide, YFYPEL, were also found after simulated gastrointestinal digestion of different milk 161 
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products, such as infant formula (Hernández-Ledesma, Quirós, Amigo, & Recio, 2007), milk 162 
and yoghurt (Dupont et al., 2010). Moreover, a study performed in humans consuming milk 163 
or yoghurt demonstrated the presence of peptides AYFYPEL and YFYPEL in the stomach 164 
and duodenum, respectively, which demostrate the resistance of this αs1-casein fragment to 165 
human digestion (Chabance et al., 1998).  166 
Several studies have suggested the role of amino acid proline making peptides less 167 
susceptible to proteolytic action (Quirós et al., 2007; Ohsawa et al., 2008), although the effect 168 
is dependent on the amino acid’s position (Gómez-Ruiz et al., 2004). The presence of two 169 
inner prolines conferred resistance to the action of endopeptidases to peptides FVAPFPEV 170 
and VAPFPEVF, but their susceptibility to aminopeptidases and mainly carboxypeptidases 171 
was different. Peptide FVAPFPEV was weakly hydrolysed into VAPFPEV and FVAPFPE 172 
(Fig. 1C), whereas VAPFPEVF was completely hydrolysed, releasing the peptide VAPFPEV 173 
(Fig. 1D). In the case of YQKFPQY, trypsin could hydrolyse the peptide bond between lysine 174 
and phenylalanine, releasing the major fragments YQK and FPQY that were detected in the 175 
digest (Fig. 1E). HLPLPLL was also totally hydrolysed by digestive enzymes, releasing 176 
HLPLPL and a minor fragment that corresponded to the active form, HLPLP (Fig. 1F). 177 
ACE-inhibitory activity of casein peptides, before and after digestion, is shown in Fig. 178 
2. The most active sequences were RYLGY, AYFYPEL, YQKFPQY, and HLPLPLL, with 179 
IC50 values of 0.5, 5.9, 19.5 and 27.6 μg mL-1, respectively. However, peptides FVAPFPEV 180 
and VAPFPEVF showed low inhibitory activity with IC50 values higher than 300 μg mL-1. 181 
The action of digestive enzymes increased the activity of peptides AYFYEPL and 182 
FVAPFPEV, disminishing the activity of the rest of analysed peptides. It is noteworthy to 183 
mention the potent ACE-inhibitory activity measured in digests obtained from peptides 184 
RYLGY (IC50 = 9.3 μg mL-1), and AYFYPEL (IC50 = 4.7 μg mL-1). This activity was notably 185 
higher than that reported for other peptides obtained under similar conditions and exhibiting 186 
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antihypertensive activity in vivo (Quirós, Hernández-Ledesma, Ramos, Amigo, & Recio, 187 
2005; Miguel et al., 2006; Hernández-Ledesma, Miguel, Amigo, Aleixandre, & Recio, 2007). 188 
 189 
3.2. ACE-inhibitory and antioxidant activities of fragments released from casein peptides 190 
 191 
The main fragments released from peptides RYLGY, AYFYPEL and YQKFPQY, 192 
after simulated gastrointestinal digestion, were chemically synthesized and their ACE-193 
inhibitory and radical scavenging activities were evaluated (Table 1). After digestion of 194 
potent ACE-inhibitory peptide RYLGY, six sequences were identified, with three of them; 195 
LGY, YLGY, and RY showing IC50 values lower than 55 μM. These sequences and the 196 
remaining precursor peptide could contribute to the activity detected in the final digest. 197 
Presence of Tyr at C-terminal position could favour the peptide binding to ACE (Igarashi et 198 
al., 2006; Tavares et al., 2011). The major peptides released from AYFYPEL, whose 199 
sequence were AYFYPE and FYPEL, showed moderate activity with IC50 values of 260.82 200 
μM and 80.60 μM, respectively. This result indicates that intact precursor peptide could be 201 
the sequence responsible for the high activity detected in the hydrolysate obtained at the end 202 
of simulated gastrointestinal digestion. Moreover, minor peptides could also contribute to this 203 
activity. Yang, Tao, Liu, & Liu (2007) found that dipeptide AY was a true inhibitor of ACE, 204 
with an IC50 value of 14.2 μM.  205 
In the case of sequence YQKFPQY, it was totally hydrolysed and major released 206 
fragments, YQK and FPQY showed higher IC50 values (312.23 μΜ and 300.74 μM, 207 
respectively) than that of the precursor peptide (20.08 μM), thus explaining the decrease of 208 
the activity detected in the final digest.  209 
Precursor casein peptides (RYLGY, AYFYPEL, and YQKFPQY), and their derived 210 
fragments after action of digestive enzymes showed ORAC-FL values higher than that of 211 
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Trolox, used as standard antioxidant. These values were ranged from 1.38 to 4.16 μmol of 212 
Trolox μmol-1 of peptide (Table 1). Presence of Tyr in all these peptides could determinate the 213 
high antioxidant activity detected. This amino acid had been previously described as 214 
responsible for radical scavenging activity of food-derived peptides (Dávalos, Miguel, 215 
Bartolomé, & López-Fandiño, 2004; Hernández-Ledesma, Dávalos, Bartolomé, & Amigo, 216 
2005; Hernández-Ledesma, Amigo, Recio, & Bartolomé, 2007). Moreover, those peptides 217 
containing two residues of Tyr were the most potent sequences identified in this study. In the 218 
case of peptides RYLGY and YQKFPQY, precursor sequences were more active than the 219 
released peptides, which could be due to the presence of two Tyr within the sequence, one of 220 
them being a C-terminal amino acid. However, peptide AYFYPE released during digestion 221 
process showed an ORAC-FL value of 4.16 μmol of Trolox μmol-1 of peptide, 1.3-times 222 
higher than that shown by its precursor peptide AYFYPEL. Deletion of Leu at C-terminal 223 
position enhanced antioxidant activity, leaves Tyr at antepenultimate position and it seems to 224 
improve radical scavenging.  225 
 226 
3.3. Antihypertensive activity of casein-peptides derived fragments 227 
 228 
 Since peptide RYLGY showed potent antihypertensive activity but low resistance to 229 
enzymatic digestion, this peptide was selected to investigate its antihypertensive activity of 230 
the major released fragments, i.e., RYLG, YLGY, RY, and YLG, after gastrointestinal 231 
digestion. Fig. 3 shows the changes in systolic blood pressure (SBP) of SHR after acute 232 
administration of 5 mg peptide kg-1 of body weight. The precursor peptide, RYLGY, notably 233 
reduced SBP after 4 post-administration, obtaining decreases around 20 mm Hg. All peptide 234 
fragments, except YLG, exerted significant hypotensive activity and no statistically 235 
significant differences were found among peptides (except for YLG). Among the released 236 
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fragments, RYLG exhibited significant decreases (p<0.05) at 2, 4 and 8 h post-237 
administration; RY at 4 and 8 h post-administration and YLGY at 2, 4, 6 and 8 h post-238 
administration. Three of the peptides assayed have Tyr as C-terminal residue as other food 239 
derived peptides that have demonstrated to be absorbed and reach blood circulation in an 240 
intact form and to exert hypotensive effects in SHR (Matsufuji et al., 1995; Matsui et al., 241 
2002; Van Platerink et al., 2006; Foltz, et al., 2007). The antihypertensive activity on SHR of 242 
peptide RY had been previously demonstrated and its effects continued for 30 h after oral 243 
administration (Saito, Wanezaki, & Imayasu, 1994). 244 
Peptide RYLG reached the maximum antihypertensive effect after 6 h post-245 
administration (-18. ± 5 mm Hg). However, ACE-inhibitory activity of this peptide was low, 246 
with an IC50 value of 224.7 μM. This result opens up the possibility that, besides ACE-247 
inhibitory activity, other molecular mechanisms underlie the mode of action of this peptide. 248 
Increased production of superoxide anion and hydrogen peroxide, reduced nitric oxide 249 
synthesis, and decreased bioavailability of antioxidants have been related with hypertension 250 
(Touyz, 2004; Sánchez et al., 2011). Supplementation with antioxidants have been shown to 251 
decrease blood pressure in animal models and humans with essential hypertension (Vasdev, & 252 
Gill, 2005). Peptide RYLG showed a notable radical scavenging activity, indicating that its 253 
antioxidant properties might contribute to its antihypertensive effect. Moreover, this peptide 254 
presents high homology with sequence RYLGYL, αS1-CN f(90–95), which has previously 255 
been described as an opioid (Loukas, Varoucha, Zioudrou, Streaty, & Klee, 1983). 256 
Hypotensive and vasodilator effects exerted by opioid peptides, such as of α-La f(50-53) 257 
(YGLF), could be mediated by interaction with opioid receptors (Nurminen et al., 2000). 258 
 259 
 260 
 261 
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4. Conclusions 262 
 263 
Antihypertensive peptides RYLGY and AYFYPEL partly resisted the action of 264 
enzymes during a process simulating gastrointestinal conditions. High ACE-inhibitory 265 
activity of these peptides was still observed after simulated gastrointestinal digestion, with 266 
IC50 values lower than 10 μΜ mL-1. All studied peptide fragments exhibited radical-267 
scavenging activity, being AYFYPE the most active peptide, and several of them also showed 268 
ACE-inhibitory activity, such as LGY, YLGY and RY. The antihypertensive activity in SHR 269 
of RYLGY peptide was as high as that found after oral administration of RYLG, YLGY, and 270 
RY, main digestion fragments. This result highlighted that in addition to the undigested 271 
fraction, other minor fragments and their combined action could contribute in the in vivo 272 
effects of RYLGY. Although ACE-inhibition could be responsible of the antihypertensive 273 
activity, other mechanisms such as vasodilatation, antioxidant and opioid activity cannot be 274 
discarded. Thus, further work will be needed to clarify the physiological relevance and 275 
mechanism of other minor digestion fragments and the molecular mechanism of action of 276 
RYLGY. 277 
 278 
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FIGURE CAPTIONS 408 
 409 
Figure 1. RP-HPLC chromatograms and peptide fragments released after simulated 410 
gastrointestinal digestion of synthetic petpides: (A) RYLGY; (B) AYFYPEL; (C) 411 
FVAPFPEV; (D) VAPFPEVF; (E) YQKFPQY and (F) HLPLPLL. 412 
 413 
Figure 2. Angiotensin-converting enzyme-inhibitory activity, expressed as IC50 (μg mL-1), of 414 
casein derived-peptides before      and after     simulated gastrointestinal digestion. Data are 415 
expressed as mean ± standard deviation (n =3). 416 
 417 
Figure 3. Effects of synthetic peptides RYLGY, RYLG, RY, YLGY, and YLG on systolic 418 
blood pressure (SBP) of spontaneously hypertensive rats (SHR) at different times after oral 419 
administration at the same dose. Data are expressed as mean ± SEM. Student’s t test was used 420 
to compare different times post-administration (n = 6, *P < 0.05).  421 
